AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03116971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 over a 60 minute IV infusion on Days 1-3 was administered for 6 cycles with each cycle lasting 3 weeks (21 days).
Study NCT02056340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study NCT02056340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00119054 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In Home Health Messaging Device
Study NCT01190774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information to health provider without patient knowledge
Description: The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
Study NCT01190774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dentist behaviour and patient expectancy
Description: patient give information about their dental anxiety to the dentist
Study NCT01655472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imaging follow up: MRI scan
Description: .1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
Study NCT01655472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imaging follow up: Ultrasonographic examination
Study NCT03781596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Retrospective evaluation of endoscopy prior to study drug
Description: Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.
Study NCT03781596 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Retrospective evaluation of endoscopy prior to study drug
Description: Once enrolled, the patient's original endoscopy will be evaluated including the images from the EGD and the biopsies for eotaxin 3 staining and eosinophilic burden.
Study NCT03781596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Survey
Description: Patient will complete symptom survey prior to starting the study drugs.
Study NCT02966665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine, Ranitidine
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
Study NCT01173822 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Ultrafiltration of residual blood
Description: The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
Study NCT01173822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrafiltration of residual blood
Description: The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
Study NCT02966665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angiotensin-II, Valsartan
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
Study NCT02966665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine
Description: Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
Study NCT02966665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123, MitoQ, BH4
Description: Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
Study NCT00479128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Starting dose: 0.8 mg/m\^2 IV Over 3-5 Seconds
Study NCT00479128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Starting dose: 225 mg/m\^2 IV Up to 90 Minutes
Study NCT00846027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study NCT00846027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel was supplied as a sterile liquid in glass vials.
Study NCT00846027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine was supplied as a sterile liquid in glass vials.
Study NCT00058318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
Study NCT00058318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine will be given 900 mg/m\^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
Study NCT02660060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Dexa Medica
Description: Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
Study NCT02660060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole Boehringer Ingelheim Pharma
Description: Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH \& Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
Study NCT03345849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Oral; Tablet
Study NCT03345849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral; Tablet
Study NCT03345849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Upadacitinib
Description: Oral; Tablet
Study NCT06219876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser treatment
Description: The laser device from Mectronic Medicale was used for LLLT. LASER treatments were to be performed every other day for a total of 10 sessions.
Study NCT06219876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High intensity laser treatment
Description: The laser device from HIRO TT (ASA, Italy) was used for HILT. LASER treatments were to be performed every other day for a total of 10 sessions.
Study NCT06219876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wrist splint
Description: wrist splints of an appropriate size in a neutral position for at least 8 hours at night for 3 months
Study NCT06371989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Image guided vacuum assisted biopsy
Description: Image guided VAB of tumor site. A needle is inserted into the affected tumor bed area using an US or stereotactic method to collect cells or tissue from a tumor mass.
Study NCT05433064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Stimulator
Description: Subjects will be implanted with 16-electrode epidural array in the T11-L1 area of the spinal cord. After 2 weeks recovery,patients will undergo a structured program of physical rehabilitation and electrical stimulation.
Study NCT00479128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
Study NCT01858285 — intervention group
Intervention type: GENETIC
Intervention: Exome and/or whole genome sequencing
Study NCT03459534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib HCl
Description: 1. Brand name/manufacturer: Supect Cap./IL-YANG PHARM. Co., Ltd.~2. Active ingredient: radotinib HCl 106.8mg (100mg as radotinib) or HCl 213.6mg (200mg as radotinib)~3. Appearance and formulation: hard capsule with a light blue cap and a body containing pale yellow powder~4. Storage conditions: Store in an airtight light proof container at room temperature.
Study NCT04008303 — intervention group
Intervention type: PROCEDURE
Intervention: Migraine surgery
Description: Surgical decompression of neuromuscular structures causing migraine headaches.
Study NCT01465867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
Study NCT01465867 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill Placebo
Description: Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
Study NCT01465867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selenium + L-Thyroxine (LT4)
Description: 83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)
Study NCT01465867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar Pill Placebo + L-Thyroxine (LT4)
Description: Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour~+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)
Study NCT01713582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX015/Birabresib
Description: OTX015/Birabresib 10 mg, 20 mg, or 40 mg capsules administered orally
Study NCT01651676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VQ11 validation
Description: Two visits per patient are planned: V1 and V2.~For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)~LABD treatment consist in β 2 agonists or anticholinergic drug.
Study NCT02797301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: synthetic test
Description: The children performed the synthetic test with no time restriction.
Study NCT02797301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerised test
Description: The children performed the computerised test with no time restriction.
Study NCT03581149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Picosulfate/Magnesium Citrate Laxative
Description: ● First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.
Study NCT03581149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L polyethylene glycol/ascorbic acid
Description: * First arm: Patients will receive sodium picosulfate/magnesium citrate (Citrafleet®) solution with an instruction leaflet.~* Second arm: Patients will receive 2L polyethylene glycol + ascorbic acid (MoviPrep®) solution with an instruction leaflet.
Study NCT02951403 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elbow arthroscopy
Description: Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
Study NCT02951403 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conservative treatment
Description: Physiotherapy protocol is introduced to patients.
Study NCT04089670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Acceptance and Commitment Therapy Intervention
Description: The intervention includes 8 modules (i.e, Away Moves, Letting Go of Control, Noticing Hooks, Stepping Back, Your Values, How You Want to Act, Goal Setting, and Making Commitments). Away Moves and Letting Go of Control, helps establish creative hopelessness, where one abandons futile struggles against negative internal experiences and accepts new solutions. These two modules also help identify experiential avoidance and focus on acceptance. Noticing Hooks and Stepping Back focus on defusion, self as context, and mindfulness. While, mindfulness is overtly addressed in the module Stepping Back it is weaved through each module. Your Values and How You Want to Act focus on helping participants identify their values. Goal Setting and Making Commitments focus on committed action. Each module ends with a practice assignment which participants are asked to engage in over the next week.
Study NCT00705913 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mitroflow Aortic Pericardial Heart Valve (CarboMedics)
Description: Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
Study NCT00705913 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carpentier-Edwards Magna Tissue Valve
Description: Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
Study NCT04552041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospekta
Description: Oral administration.
Study NCT04552041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration.
Study NCT04416165 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-FDG and 68Ga-DOTA-FAPI -04 PET/CT
Description: Each subject receive a single intravenous injection of 18F-FDG and 68Ga-DOTA-FAPI-04, and undergo PET/CT imaging within the specified time.
Study NCT01550029 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling/Healthy Lifestyle
Description: A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle.
Study NCT02980991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
Study NCT02980991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
Study NCT04245306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized test for pragmatic inferences
Description: Computerized tests
Study NCT04245306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: computerized test for pragmatic inferences
Description: Computerized tests
Study NCT04738240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intra-operative endoscopy
Description: Intra-operative endoscopy to assess rectal anastomosis
Study NCT04551898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-DXP593
Description: Intravenous (IV) infusion administered over 30 to 90 minutes at a dose as specified in the treatment arm
Study NCT04551898 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match BGB-DXP593 administered as specified in the treatment arm
Study NCT01393483 — intervention group
Intervention type: OTHER
Intervention: serum and tissue mesothelin
Description: Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.~Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs.
Study NCT01393483 — intervention group
Intervention type: OTHER
Intervention: serum and tissue mesothelin
Description: Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
Study NCT01393483 — intervention group
Intervention type: OTHER
Intervention: serum and tissue mesothelin
Description: Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
Study NCT03735017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Interactive Virtual Reality Walking
Description: Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.
Study NCT03735017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Virtual Reality Walking
Description: Individuals will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective.~Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart.
Study NCT03237390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03237390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03237390 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03237390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT03537001 — intervention group
Intervention type: OTHER
Intervention: Penthrox
Description: Self-administration of penthrox by the patient under the supervision of a physician trained in its administration, in strict compliance with its MA.
Study NCT01332851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships (PFR)
Description: PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
Study NCT01332851 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resource and Referral
Description: Needs assessment, followed with a resource packet sent by mail
Study NCT04119063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: powered orthosis
Description: Novel powered leg brace to provide assistance during walking.
Study NCT03877016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
Study NCT03877016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS Eco2 or actiTENS, both admitted and reimbursed in FRANCE according to regulation
Study NCT01728974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharyngeal topical anesthesia
Description: Pharyngeal topical anesthesia will be performed using 4% lidocaine spray